Avanir Pharmaceuticals closes community offering of 20.

Avanir intends to utilize the net proceeds from the general public providing for general corporate reasons, such as, but are not really limited by, funding NUEDEXTA commercial actions, financing our ongoing and potential clinical trials, financing the commercial release of AVP-825, if authorized, and for administrative and general expenses. We may also work with a portion of the web proceeds to repay exceptional indebtedness and/or acquire or spend money on complementary businesses, products and technologies or even to fund the advancement of such complementary businesses, technologies or products that people might acquire in a stock-based acquisition.